Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention (CDC)
---Centers for Medicare and Medicaid Services (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Clinical Trial Data From China
---CMMI Models: GLOBE and GUARD
---Funding for Section 317
---Funding for Strategic National Stockpile
---OMB Federal Research Proposed Rule
---Pandemic Preparedness
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Vaccine Access & Compensation

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---Oversight Pharmacy Benefit Managers

Artificial Intelligence (AI)

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights

Compulsory Licensing
---28 U.S.C. 1498 - Patent and copyright cases

Data Privacy
---H.R.8413: SECURE Data Act
---Implementation of BIOSECURE Act

Drug Patenting
---H.R.3160/S.1553: PREVAIL Act
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---H.R.9142: Prohibiting Adversarial Patents Act of 2026
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act of 2025
---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA)
---S.2658: Medication Affordability and Patient Integrity Act
---S.3014: Ensuring Timely Access to Generics Act of 2025
---Department of Commerce Patent Valuation Fee Proposal
---Patent Litigation Reform
---Patent Tax/fees
---PTAB Reform
---Restrictions on Intellectual Property Rights
---Section 101 Modernization

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Intellectual Property Enforcement
---China

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Centers for Disease Control and Prevention (CDC)
---Centers for Medicare and Medicaid (CMS)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CICP
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Funding for Strategic National Stockpile
---Funding for Women's Health Research
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Influenza Planning & Response
---MCM PRV Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---Pediatric Priority Review Voucher
---Prescription Drug User Fee Act (PDUFA) VIII Implementation
---Project Bioshield
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Section 317 Immunization Program
---Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program

340B Drug Discount Program
---H.R.5256: 340B ACCESS Act
---H.R.9504: Tax Exempt Hospital Transparency Act
---Program Implementation & Oversight
---Rebate Models
---SECURE 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act)
---Implementation of BIOSECURE Act
---MCM PRV Program Reauthorization
---National Defense Authorization Act 2027
---Reasonable Pricing Clauses in BARDA Contracts
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---VICP Loopholes

Biosimilars
---S.1414: Expedited Access to Biosimilars Act
---Biosimilars Competition (General)
---Biosimilar Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China
---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft

Data Privacy
---H.R.8413: SECURE Data Act
---Clinical Trial Data in China
---Implementation of BIOSECURE Act

Diversity & Inclusion
---H.R.3521: Clinical Trial Modernization Act
---Decentralized Clinical Trials

Drug Evaluation and Review
---FDA Hiring Flexibility

Drug Importation

Drug Manufacturing, Quality & Distribution
---S.3788: CLEAR Labels Act
---Advanced Manufacturing
---Compounding Pharmacies
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act
---H.R.6485/S.43: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1041: Affordable Prescriptions for Patients Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---S.2658: Medication Affordability and Patient Integrity Act

Drug Pricing
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.527: Prescription Pricing for the People Act
---S.832: Ensuring Pathways to Innovative Cures (EPIC) Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1302: Increasing Transparency in Generic Drug Application
---Access to Innovative Treatments Act
---Biosimilar Red Tape Elimination Act
---CMMI: GLOBE and GUARD Models
---CMMI Authority
---DRUG Act
---Ensuring Access to Generic Medications Act
---Ensuring Timely Access to Generics
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Implementation of ORPHAN Cures Act
---International Pricing Policies
---Medicare Drug Price Negotiation Act
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---National Coverage Determination
---Most Favored Nation Drug Pricing Proposals
---Patient Cost-Sharing and Implementation
---Senate Finance Committee Minority RFI on Drug Pricing
---Tariffs

Efforts to Expand the Bio Economy & Bio Manufacturing

Foreign Drug Data Protection Law
---Implementation of BIOSECURE Act

Generic Drug Entry
---H.R.6485/S.43: Skinny Labels, Big Savings Act
---S.1095: Stop STALLING Act
---Generic Drug Application Review Reforms

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---Alternative Payment Arrangements for Gene Therapies
---CMMI (GENEROUS Model)
---CMMI: GLOBE and GUARD Models
---Drug Benefit Design
---International Pricing Policies
---Medicaid VBPs for Patients (MVP) Act
---Most Favored Nation Drug Pricing Proposals
---Pricing and Rebates

National Defense
---Medical Countermeasure Priority Review Voucher Reauthorization
---National Defense Authorization Act of 2027

National Security
---S.3741: Biosecurity Modernization and Innovation Act of 2026
---Clinical Trial Data in China
---CMMI: GLOBE and GUARD Models
---Implementation of BIOSECURE Act
---International Pricing Policies
---Medical Countermeasure Priority Review Voucher Reauthorization
---NSC/OSTP priorities
---Nucleic acid synthesis security and biotechnology governance
---Most Favored Nation Drug Pricing Proposals

Opioid Crisis
---Non-Opioid Analgesics

Orphan Drug Issues
---S.705: Innovation in Pediatric Drugs Act of 2025
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act

Pandemic Preparedness
---Drug Supply Chain Management
---R&D Funding for Medical Countermeasures
---Supply Chain Issues
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Rare Pediatric Disease Priority Review
---S.822: Scientific EXPERT Act
---Rare Disease Pilot Program

Reimbursement and Coverage of Innovative Products
---S.864/H.R.6423: HELP Copays Act
---S.1816: Improving Seniors Timely Access to Care Act of 2025
---Access to Innovative Treatments
---Administrative Rebate Rule
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Medicaid VBPs for Patients (MVP) Act
---Medicare Drug Price Negotiation Act
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Prescription Drug Price Relief Act
---Prior Authorization Reform
---SAFE STEP Act
---Step Therapy

Vaccines and Infectious Diseases
---Adult Immunization
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---PASTEUR ACT
---SAFE STEP Act
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Modernization Act
---Vaccine Injury Compensation Program
---Vaccine Safety
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), White House Office, Office of Management & Budget (OMB), Natl Security Council (NSC), Patent & Trademark Office (PTO), Treasury - Dept of, Federal Trade Commission (FTC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention Vaccine Programs
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Medical Countermeasure Priority Review Voucher Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---VICP/CICP

Biodefense Research, Development and Procurement Issues
---Ebola BDBV Outbreak
---Gene Editing
---Hanta Virus
---Medical Countermeasure Priority Review Voucher Reauthorization
---National Defense Authorization Act 2027
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---WHO Pandemic Preparedness Accord

Pandemic Preparedness
---Medical Countermeasure Priority Review Voucher Reauthorization
---Reauthorization of PAHPA
---Supply Chain Issues

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Administration for Strategic Preparedness and Response (ASPR)
---Biomedical Advanced Research and Development Authority (BARDA)
---Centers for Disease Control and Prevention (CDC)
---Food & Drug Administration (FDA)
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institutes of Health (NIH)

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Medical Countermeasures
---Funding for Section 317
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act (IRA) of 2022
---MCM PRV Reauthorization
---Pandemic Flu
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---VICP/CICP

Antimicrobial Resistance

Biodefense Research, Development and Procurement Issues
---Gene Editing
---HHS Reorganization
---Medical Countermeasure Priority Review Voucher Reauthorization

CDC Reform

Pandemic Preparedness
---Medical Countermeasure Priority Review Voucher Reauthorization
---R&D Funding for Medical Countermeasures

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Federal Trade Commission (FTC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---CMMI: GLOBE and GUARD Models
---Drug Pricing
---Pandemic Preparedness - R&D Funding for Medical Countermeasures
---Vaccines and Infectious Diseases

340B Drug Discount Program
---H.R.5256: 340B ACCESS Act
---H.R.9504: Tax Exempt Hospital Transparency Act
---Program Implementation & Oversight
---PROTECT 340B Act
---Rebate Models
---SECURE 340B Act
---SUSTAIN 340B Act

Alternative Funding Programs

Biosimilars
---Biosimilars Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution

Cell & Gene Therapy
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Data Privacy
---H.R.8413: SECURE Data Act

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Compounded Medicines
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---S.43/H.R.6485: Skinny Labels, Big Savings Act
---S.527: Prescription Pricing for the People Act
---S.1095: Stop STALLING Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---S.1097: Interagency Patent Coordination and Improvement Act
---Patent Thickets
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.1492: Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672: Maintaining Investments and New Innovation (MINI) Act
---H.R.5391/S.2764: Protecting Patient Access to Cancer and Complex Therapies Act
---S.526: Pharmacy Benefit Manager Transparency Act
---S.1096: Preserve Access to Affordable Generics and Biosimilars Act
---CMMI: GLOBE and GUARD Models
---CMMI Authority
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Most Favored Nation Drug Pricing Proposals
---Patient Cost-Sharing and Implementation
---PBM Reform
---Strengthening Innovation in Medicare and Medicaid Act

Foreign Drug Data Protection Laws

Medicaid
---S.526: Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---CMMI (GENEROUS Model)
---CMMI: GLOBE and GUARD Models
---Drug Benefit Design
---Medicaid Drug Rebate Program
---Most Favored Nation in Medicaid
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2027

Opioid Crisis
---Non-Opioid Analgesics

Orphan Drug Issues
---Implementation of ORPHAN Cures Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Pediatric Priority Review Voucher Program Reauthorization

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
---S.864/H.R.6423: HELP Copays Act
---CMMI Authority

Vaccines and Infectious Diseases
---Adult Immunization
---Countermeasures Injury Compensation Program
---MCM Manufacturing & Capacity
---Medical Countermeasure Priority Review Voucher Reauthorization
---Vaccine Injury Compensation Program
---Vaccine Safety and Quality
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Banking Policy Impacting Emerging Companies
---Regulatory Burden

Capital Formation Incentives
---H.R.3323: Helping Startups Continue To Grow Act
---H.R.3339: Equal Opportunity for All Investors Act of 2025
---H.R.3348: Accredited Investor Definition Review Act
---H.R.3382/S.2924: Small Entity Update Act
---H.R.3394: Fair Investment Opportunities for Professional Experts Act
---H.R.4430: Expanding WKSI Eligibility Act

Capital Market Enhancements
---Accredited Investor Definition
---Public Float Threshold Update
---Small Business Capital Formation Enhancement Act

Mergers and Acquisitions

Small Business Innovation Research (SBIR) Program
---H.R.3169/S.1573: SBIR/STTR Reauthorization Act of 2025
---H.R.4777: INNOVATE Act
---H.R.5100: To extend the SBIR and STTR programs, and for other purposes.
---S.3971: Small Business Innovation and Economic Security Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Vaccines and Infectious Diseases
---VICP/CICP

Capital Formation Incentives
---Net Operating Loss Advance Refunds

Orphan Drug Issues
---Implementation of ORPHAN Cures Act

Pandemic Preparedness

Research & Development Tax Credit Reforms
---H.R.1: One Big Beautiful Bill Act
---American Innovation and R&D Competitiveness Act
---Expensing of R&D Expenditures
---Tax Relief for American Families and Workers Act

Vaccines and Infectious Disease
---Countermeasure Injury Compensation Fund Amendment Act
---Vaccine Injury Compensation Modernization Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment
---Outbound Investment Security Program

Drug Importation

Drug Pricing
---CMMI: GLOBE and GUARD Models
---International Pricing Policies
---Most Favored Nation Drug Pricing Proposals
---Reference Pricing in Drug Reimbursement
---Tariffs

Foreign Drug Data Protection Laws
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes.
---Implementation of BIOSECURE Act
---Implementation of COINS

Global Supply Chain Resiliency

Incentives for Domestic Manufacturing

Intellectual Property International Enforcement
---China

Synthetic Biotech

Tariffs

Trade Relations
---Section 232

US-China Trade Relations
---H.R.9102: BINSA Act
---Implementation of COINS
---IP Provisions

World Health Organization (WHO)
---WHO Pandemic Preparedness Accord

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Natl Security Council (NSC), White House Office, Treasury - Dept of, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes